Endocrinology

Top Story

New combination insulin, GLP1 receptor agonists in development

September 24, 2016

The French biotechnology company Adocia announced the launch of a program to develop two new drugs combining insulin and GLP-1 receptor agonists to treat type 2 diabetes, according a company press release.

The combinations — insulin glargine (Lantus, Sanofi) plus dulaglutide (Trulicity, Eli Lilly) and insulin glargine plus liraglutide (Vicotza, Novo Nordisk) — will use Adocia’s BioChaperone technology, which solubilizes and stabilizes insulin glargine in an aqueous solution. This allows it to combine with the two GLP-1 receptor agonists.

Meeting News CoverageVideo

VIDEO: Consortium aims to address thyroid issues and pregnancy

September 23, 2016
DENVER — In this video exclusive, Tim Korevaar, MD, MSc, a PhD student at Erasmus University Medical Center in Rotterdam, Netherlands, discusses a consortium…
Meeting News CoverageVideo

VIDEO: Thyroid imaging approaches not ‘one-size fits all’

September 23, 2016
DENVER — In this video exclusive, Megan R. Haymart, MD, assistant professor of medicine at the University of Michigan Medical School in Ann Arbor, discusses…
Meeting News Coverage

Patients with Hashimoto's thyroiditis require similar T4 levels regardless of body weight

September 23, 2016
DENVER — Thyroxine requirements in Hashimoto’s thyroiditis are similar for patients with normal weight or overweight, study data show. “The analysis…
Meeting News Coverage

Recommendations needed for TPOAb cut-off levels during pregnancy

September 23, 2016
DENVER — The presence of thyroid peroxidase antibodies during pregnancy may affect thyroid function, but no recommended cut-off ranges to identify thyroid…
More News Headlines »
CME CNE CPE

The Emerging Biosimilar Therapeutic Landscape: Scientific Foundations and Clinical Implications

This activity is supported by an educational grant from Boehringer-Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

Recent processes have been established to facilitate the production, validation, and utilization of biosimilars…
More »
Video
Meeting News Coverage

VIDEO: Empagliflozin significantly reduces microvascular outcomes

September 16, 2016
More »
Featured
ADA 2016

ADA 2016

CME

Obesity Consults® ObesityForum® 2015 Highlights

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc. and Novo Nordisk, Inc.

Obesity has increased dramatically in the past 20 years and is considered a health care epidemic in the United States…
More »
in the journals

Get the best of the journals.
Read abstracts, search and filter results, gain perspective, view graphics.

Go »
Current Issues
View the Current Issues
morganatic-roan
morganatic-roan